22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release here
  • Home
  • About Us
    • Our Company
    • Our Leadership Team
    • Board of Directors
  • Reduced Nicotine Tobacco
    • VLN®
    • Clinical Studies & Commentaries
  • Hemp/Cannabis Innovation
    • GVB Biopharma
  • Hops Research
  • News
  • Investors
    • Overview
    • New Investor / Latest Resources
    • Events
    • News
    • Stock Data
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports
    • FAQs
  • Contact Us

Sitemap

22nd Century Group, Inc. Sitemap

  • Home
  • About Us
    • Our Company
    • Leadership Team
    • Board of Directors
  • Reduced Nicotine Tobacco
    • VLN®
    • Clinical Studies & Commentaries
      • Clinical Studies on Benefits of Using Reduced Nicotine Content Cigarettes
      • On-Going Clinical Studies Using Reduced Nicotine Content Cigarettes
      • Commentaries & Opinion Pieces on Reduced Nicotine Content Cigarettes
  • Hemp/Cannabis Innovation
    • GVB Biopharma
  • Hops Research
  • News & Media
  • Investors
    • Overview
    • New Investor / Latest Resources
    • Events
    • News
      • Press Releases
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Trades
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports
    • FAQs
  • Contact Us
  • Privacy Policy / CCPA
  • Disclaimer
  • Sitemap
© 2022 22nd Century Group, Inc. All Rights Reserved.
Privacy Policy / CCPA Disclaimer Sitemap